Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    15488216 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
Condition: Malaria
Interventions: Biological: R21/Matrix-M1;   Other: Saline
2 Completed Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Condition: Malaria, Vivax
Interventions: Drug: Peptides (N,R&C) formulated in Montanide ISA 720;   Drug: Peptides (N,R&C) formulated in Montanide ISA 51;   Other: Placebo

Indicates status has not been verified in more than two years